McLean Asset Management Corp Has $490,000 Holdings in Johnson & Johnson (NYSE:JNJ)

McLean Asset Management Corp grew its position in Johnson & Johnson (NYSE:JNJ) by 6.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 3,390 shares of the company’s stock after purchasing an additional 198 shares during the quarter. McLean Asset Management Corp’s holdings in Johnson & Johnson were worth $490,000 as of its most recent filing with the SEC.

A number of other hedge funds have also bought and sold shares of the company. Quarry LP acquired a new stake in shares of Johnson & Johnson during the 2nd quarter worth approximately $49,000. Ashburton Jersey Ltd acquired a new stake in Johnson & Johnson in the second quarter worth $8,771,000. Mattson Financial Services LLC bought a new stake in Johnson & Johnson in the second quarter valued at $3,407,000. First Financial Bank Trust Division raised its holdings in shares of Johnson & Johnson by 1.3% during the third quarter. First Financial Bank Trust Division now owns 62,803 shares of the company’s stock valued at $10,178,000 after purchasing an additional 779 shares during the period. Finally, Davis Capital Management boosted its position in shares of Johnson & Johnson by 4.4% during the 3rd quarter. Davis Capital Management now owns 10,432 shares of the company’s stock worth $1,691,000 after purchasing an additional 441 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was purchased at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now directly owns 1,000 shares of the company’s stock, valued at approximately $147,220. This trade represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.16% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on JNJ. Stifel Nicolaus dropped their price target on Johnson & Johnson from $170.00 to $155.00 and set a “hold” rating on the stock in a research note on Thursday, January 23rd. Royal Bank of Canada reiterated an “outperform” rating and issued a $181.00 target price on shares of Johnson & Johnson in a report on Thursday, January 23rd. Barclays boosted their price target on shares of Johnson & Johnson from $159.00 to $166.00 and gave the company an “equal weight” rating in a research note on Tuesday. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, January 25th. Finally, Guggenheim boosted their target price on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Stock Up 1.1 %

Shares of NYSE:JNJ opened at $152.78 on Friday. The company has a market capitalization of $367.82 billion, a PE ratio of 22.97, a price-to-earnings-growth ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The business has a fifty day moving average price of $147.73 and a two-hundred day moving average price of $156.10.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.35%. The business had revenue of $22.52 billion during the quarter, compared to the consensus estimate of $22.44 billion. During the same quarter last year, the company posted $2.29 earnings per share. The firm’s quarterly revenue was up 5.3% compared to the same quarter last year. Analysts forecast that Johnson & Johnson will post 10.56 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.25%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.